Literature DB >> 21695286

Nanotechnology in ocular delivery: current and future directions.

Yasmin Sultana1, D P Maurya, Z Iqbal, M Aqil.   

Abstract

Our knowledge in the field of ocular drug delivery is rapidly expanding. An increase in the understanding of ocular drug absorption and disposition vis-à-vis developments in nanotechnology has led to the emergence of many of the nanotechnology-based ocular drug delivery systems including nanoparticles, microemulsions, liposomes, solid lipid nanoparticles, light-sensitive nanocarrier systems, etc. The need to develop effective treatments for posterior eye segment diseases is more important than surface delivery. Treatment of blinding diseases of the eye, such as proliferative retinopathy or macular degeneration, requires effective and safe delivery of drugs to posterior eye segment tissues, and recent advances in nanotechnology have demonstrated successful outcomes. Nanoscientists should focus their efforts on nano-ophthalmology. This review describes the current status and progress made so far, and the course that needs to be pursued in the future. Copyright 2011 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21695286     DOI: 10.1358/dot.2011.47.6.1549023

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  11 in total

Review 1.  Nanotechnology in corneal neovascularization therapy--a review.

Authors:  Lilian Gonzalez; Raymond J Loza; Kyu-Yeon Han; Suhair Sunoqrot; Christy Cunningham; Patryk Purta; James Drake; Sandeep Jain; Seungpyo Hong; Jin-Hong Chang
Journal:  J Ocul Pharmacol Ther       Date:  2013-02-20       Impact factor: 2.671

2.  Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs.

Authors:  Punit P Shah; Pinaki R Desai; Apurva R Patel; Mandip S Singh
Journal:  Biomaterials       Date:  2011-11-26       Impact factor: 12.479

Review 3.  Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.

Authors:  I Bravo-Osuna; V Andrés-Guerrero; P Pastoriza Abal; I T Molina-Martínez; R Herrero-Vanrell
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

Review 4.  Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma.

Authors:  Kang Zhang; Liangfang Zhang; Robert N Weinreb
Journal:  Nat Rev Drug Discov       Date:  2012-06-15       Impact factor: 84.694

5.  Aqueous nanomicellar formulation for topical delivery of biotinylated lipid prodrug of acyclovir: formulation development and ocular biocompatibility.

Authors:  Aswani Dutt Vadlapudi; Kishore Cholkar; Ramya Krishna Vadlapatla; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2013-11-05       Impact factor: 2.671

Review 6.  Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation.

Authors:  Anil Kumar; Fei Chen; Anbu Mozhi; Xu Zhang; Yuanyuan Zhao; Xiangdong Xue; Yanli Hao; Xiaoning Zhang; Paul C Wang; Xing-Jie Liang
Journal:  Nanoscale       Date:  2013-09-21       Impact factor: 7.790

Review 7.  The utility and risks of therapeutic nanotechnology in the retina.

Authors:  Melanie Scheive; Saeed Yazdani; Amir R Hajrasouliha
Journal:  Ther Adv Ophthalmol       Date:  2021-03-22

8.  Chondroitin sulfate functionalized mesostructured silica nanoparticles as biocompatible carriers for drug delivery.

Authors:  Juqun Xi; Jin Qin; Lei Fan
Journal:  Int J Nanomedicine       Date:  2012-10-09

9.  Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy.

Authors:  Raghavendra Gowda; Nathan R Jones; Shubhadeep Banerjee; Gavin P Robertson
Journal:  J Nanomed Nanotechnol       Date:  2013-12

Review 10.  Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents.

Authors:  Eliana B Souto; João Dias-Ferreira; Ana López-Machado; Miren Ettcheto; Amanda Cano; Antonio Camins Espuny; Marta Espina; Maria Luisa Garcia; Elena Sánchez-López
Journal:  Pharmaceutics       Date:  2019-09-06       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.